CD14抑制改善大肠杆菌脓毒症狒狒模型的生存并减轻血栓炎症与心肺功能障碍
该研究在致死性大肠杆菌脓毒症狒狒模型中,于细菌攻击前30分钟静脉给予抗CD14抑制性抗体23G4。结果显示抗CD14治疗可延长生存、抑制组织因子依赖的凝血激活、增强纤溶、阻止补体激活并减轻炎症反应,提示其保护作用。
要点
- 抗CD14抗体23G4在E coli攻击前30分钟静脉推注给药。
- 治疗组存活延长,部分动物达到7天存活标准。
- 抗CD14抑制凝血激活、增强纤溶并减轻补体激活与炎症。
核心结论
- 抗CD14治疗在致死性大肠杆菌脓毒症狒狒模型中具有保护作用,可改善生存并减轻血栓炎症与器官功能障碍。
研究设计与样本
- 采用致死性大肠杆菌脓毒症狒狒模型,设两个实验组(每组n=5):单纯大肠杆菌攻击组和抗CD14抗体23G4预处理组。
- 抗CD14抗体于大肠杆菌攻击前30分钟经静脉推注给药。
主要发现
- 抗CD14组中2只动物达到7天终点存活标准,3只动物生存时间较未治疗动物显著延长。
- 未治疗动物发生多器官衰竭并在30小时内死亡。
- 抗CD14通过抑制组织因子依赖途径减少凝血激活,尤其在对存活动物中,并通过强烈抑制纤溶酶原激活物抑制剂1增强纤溶。
- 抗CD14阻止大肠杆菌诱导的强烈补体激活,表现为C3b、C5a和sC5b-9显著降低。
- 抗CD14改善生命体征、器官功能生物标志物、细菌清除以及白细胞和纤维蛋白原消耗,并减少中性粒细胞活化、细胞死亡、LPS水平和促炎细胞因子(TNF、IL-6、IL-1β、IL-8、IFN-γ、MCP-1),在存活动物中较非存活动物更显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During sepsis, gram-negative bacteria induce robust inflammation primarily via lipopolysacharride (LPS) signaling through TLR4, a process that involves the glycosylphosphatidylinositol (GPI)-anchored receptor CD14 transferring LPS to the Toll-like receptor 4/myeloid differentiation factor 2 (TLR4/MD-2) complex. Sepsis also triggers the onset of disseminated intravascular coagulation and consumptive coagulopathy. OBJECTIVES: We investigated the effect of CD14 blockade on sepsis-induced coagulopathy, inflammation, organ dysfunction, and mortality. METHODS: We used a baboon model of lethal Escherichia (E) coli sepsis to study two experimental groups (n = 5): (a) E coli challenge; (b) E coli challenge plus anti-CD14 (23G4) inhibitory antibody administered as an intravenous bolus 30 minutes before the E coli. RESULTS: Following anti-CD14 treatment, two animals reached the 7-day end-point survivor criteria, while three animals had a significantly prolonged survival as compared to the non-treated animals that developed multiple organ failure and died within 30 hours. Anti-CD14 reduced the activation of coagulation through inhibition of tissue factor-dependent pathway, especially in the survivors, and enhanced the fibrinolysis due to strong inhibition of plasminogen activator inhibitor 1. The treatment prevented the robust complement activation induced by E coli, as shown by significantly decreased C3b, C5a, and sC5b-9. Vital signs, organ function biomarkers, bacteria clearance, and leukocyte and fibrinogen consumption were all improved at varying levels. Anti-CD14 reduced neutrophil activation, cell death, LPS levels, and pro-inflammatory cytokines (tumor necrosis factor, interleukin (IL)-6, IL-1β, IL-8, interferon gamma, monocyte chemoattractant protein-1), more significantly in the survivors than non-surviving animals. CONCLUSIONS: Our results highlight the crosstalk between coagulation/fibrinolysis, inflammation, and complement systems and suggest a protective role of anti-CD14 treatment in E coli sepsis.
引用
- Keshari RS, Silasi R, Popescu NI, et al. CD14 inhibition improves survival and attenuates thrombo-inflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis. J Thromb Haemost. 2020. PMID: 33174372. doi:10.1111/jth.15162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。